Pulmonary Medication Toolkit: Is yours up to date?
|
|
- Frederica Parker
- 5 years ago
- Views:
Transcription
1 Pulmonary Medication Toolkit: Is yours up to date? Michelle Schymik, PharmD, BCPS Pharmacist for Deaconess Health System Overview Assuming basic knowledge of pulmonary diseases FEEL FREE TO ASK ME ANY QUESTIONS! Focus on pulmonary fibrosis Focus on asthma guidelines update Focus on COPD guideline update Maximizing the use of inhaled medications Objectives List a medication recommended to treat idiopathic pulmonary fibrosis State one change from the GINA guidelines to apply to care of an asthma patient Demonstrate ability to list treatment for a patient with COPD based upon 2017 GOLD guidelines State the medication category and be prepared to counsel a patient for two new inhalers Explain techniques to improve inhaler adherence 1
2 Having Fun with Technology!! Text MICHELLESCHY461 (this is the text message) to (this is who or the phone number you text) Focus on Pulmonary Fibrosis 2
3 Pulmonary Fibrosis Background Idiopathic pulmonary fibrosis 1 Unknown origin + chronic, progressive, fibrotic interstitial lung disease Presents age>45 years (often 6 th or 7 th decade) More men than women Risk factors: Smoking GERD Exposure to metal/wood dust Genetic pre-disposition Age Other types: Familial or Drug-Induced (amiodarone, bleomycin, and nitrofurantoin) Pulmonary Fibrosis Background Idiopathic pulmonary fibrosis 1 Symptoms gradually worse over 6M Cough Wt loss Fever Fatigue Arthralgia/myalgia Symptoms often 1-2 years before diagnosis (often referred to cardiologist for DOE) Overlap with co-morbidities (COPD, PH, GERD, VTE, CAD) Survival often 2.5 years after diagnosis Die from disease (60%), cardiovascular disease, thromboembolic disease Pulmonary Fibrosis and Targets for Medicine Epithelial-fibroblastic disease 1 Damage Irritant exposure (smoke, pollutant, dust, virus, GERD, aspiration) in susceptible host damages alveolar epithelium Attempted Repair Abnormal activation of alveolar epithelial cells releases fibrotic cytokines and growth factors which repair with fibrosis Tumor necrosis factor- (TNF- ), transforming growth factor- (TGF- ), platelet-derived growth factor, insulin-like growth factor-1, endothelin-1 Interferon-γ1b Permanent Fibrosis Result is irreversible destruction of lung tissue 3
4 Pulmonary Fibrosis Guidelines for Treatment ATS/ERS/JRS/ALAT Clinical Practice Guidelines: Treatment of Idiopathic Pulmonary Fibrosis 1,2 Treat co-morbid conditions GERD, OSA, COPD, CAD Smoking cessation Vaccination influenza and pneumococcal Oxygen Use if hypoxemia at rest of with exercise (PaO 2<55 mmhg or oxygen saturation<88%) Goal=oxygen saturation>90% at rest, with sleep, and with exertion Weight loss if overweight Pulmonary rehab for exercise Pulmonary Fibrosis Guidelines for Treatment STRONG RECOMMENDATION AGAINST USE 2 Anticoagulation with Warfarin 2012 study of 145 pts taking warfarin vs. placebo- stopped early due to lack of benefit and increased mortality (RR=4.73) Imatinib (Gleevec ) Selective tyrosine kinase inhibitor against PDGF receptors Inhibit lung fibroblast-myofibroblast proliferation and inhibit cellular matrix production Study vs. placebo in 119 pts no change in mortality or disease progression, more ADRs Combination prednisone, azathioprine, and N-acetylcysteine Higher mortality (11% vs. 1%), more hospitalizations (29% vs. 8%), more ADRs (31% vs. 9%) Ambrisentan (Letairis ) Selective endothelin receptor (ER-A) antagonist Study vs. placebo in 492 pts - Increased disease progression and mortality (with or without PH) Pulmonary Fibrosis Guidelines for Treatment CONDITIONAL RECOMMENDATION AGAINST USE 2 Sildenafil Phosphodiesterase-5 inhibitor No improvement in 6MWT. Some improvement in dyspnea and QOL Macitentan and Bosentan Dual endothelin receptor (ER-A and ER-B) antagonist Bosentan vs. placebo in 2 studies no effect on mortality or symptoms Macitentan vs. placebo no effect on mortality or disease progression N-acetylcysteine alone Two studies (Japanese study and arm of triple therapy) no change in FVC decline CONDITIONAL RECOMMENDATION FOR USE Antiacid therapy for pts with GERD (found in 90% of IPF pts) to prevent aspiration 4
5 Pulmonary Fibrosis Guidelines for Treatment CONDITIONAL RECOMMENDATION FOR USE 2 Nintedanib (Ofev ) approved 10/14 Tyrosine kinase inhibitor (non-selectively targets vascular endothelial growth factor, fibroblast growth factor, and PDGF receptors) 12-month trial (150mg BID) - lower annual rate of decline in FVC and fewer exacerbations vs. placebo INPULSIS-1 and INPULSIS-2: Two 52-week trials Stat sig improvement in FVC (>10% improvement) vs. placebo No difference in mortality or exacerbations More adverse events Pts in studies had mild-moderate IPF $96,000 per year Outcomes: *Slow progression *Decrease exacerbation? Pulmonary Fibrosis Guidelines for Treatment Nintedanib (Ofev ) 3 Dosing: 150mg po BID (12h apart) with food Decrease dose to 100mg BID for mild hepatic impairment; Avoid moderate/severe Do not chew or crush Drug Interactions P-gp and CYP3A4 inhibitors may increase effect Smoking decreased effect Precautions/Side Effects: Elevated liver enzymes (14%) baseline and periodic AST, ALT, bili Check pregnancy test at baseline (can cause fetal harm) Arterial thrombotic effects (avoid if risk of CV disease) Risk of increased bleeding Nausea (24%), vomiting (12%), diarrhea (62%), abdominal pain(15%), GI perforation Diarrhea lead to: *Dose reduction in 11% *Discontinuation in 5% Nausea lead to: *Discontinuation in 2% Vomiting lead to: *Discontinuation in 1% Pulmonary Fibrosis Guidelines for Treatment CONDITIONAL RECOMMENDATION FOR USE 2 Pirfenidone (Esbriet ) approved 10/14 Anti-fibrotic - combined anti-inflammatory, antioxidant, and anti-fibrotic effects Inhibits Tumor necrosis factor- (TNF- ) and transforming growth factor- (TGF- ) Initial study (stopped early) fewer exacerbations, less O 2 desaturation during 6MWT, and less decrease in FVC CAPACITY 72-week pooled data 2403mg/day showed sig less FVC decline. More side effects Individual trials one showed benefit and other showed no benefit in FVC $94,000 per year ASCEND (more strict inclusion) less decrease in FVC at 52 weeks, improved 6MWT, improved progression free survival. More side effects Outcomes: Pts in studies had mild-moderate IPF *Slow progression 5
6 Pulmonary Fibrosis Guidelines for Treatment Pirfenidone (Esbriet ) 4 Dosing: 801mg po TID (with food) Dose is titrated up over 14 days Decrease dose for hepatic or renal insufficiency Precautions/Side Effects: Elevated liver enzymes baseline and periodic AST, ALT, bilirubin Photosensitivity GI disorders nausea, vomiting, dyspepsia, GERD, abdominal pain Rash (rare to cause discontinuation) Drug Interactions Moderate (Cipro) and Strong (fluvoxamine) CYP1A2 increase Pirfenidone Smoking decreases effect Pulmonary Fibrosis Guidelines for Treatment Lung transplant IPF now replaces COPD as reason for transplant 2 Refer to transplant center at diagnosis 5-year survival after lung transplant for IPF is 50-56% No difference in survival single vs. double-lung transplant higher No recommendation in guidelines Treatment of acute exacerbation (AE-IPF) 2 Rule out infectious causes Oxygen + Methylprednisolone 2mg/kg/day IV x 2 weeks then taper 6
7 Pulmonary Fibrosis Guidelines for Treatment 5 Pulmonary Fibrosis Future Medications 6 Compound Mechanism/Target Role of Attacking Target PRM-151 Recombinant human protein called Pentraxin-2 Active at site of tissue damage IW001 Prevents immune response to activated Type V collagen Presents lung damage TD139 Inhibitor of the galactoside Prevents fibrosis development BMS Lysophosphatidic acid-1 receptor antagonist Blocks development of fibrosis FG-301 Monoclonal antibody against connective tissue growth factor Prevents tissue remodeling and fibrosis Lebrikizumab Monoclonal antibody against interleukin (IL)-13 Fixes high level found in IPF Tralokinumab Human IL-13-neutralizing monoclonal antibody Fixes high level found in rapidly progressing IPF SAR Bispecific antibody that neutralizes IL-4 and IL-13 Prevent fibrosis Simtuzumab Monoclonal antibody against lysyl oxidase-like 2 (LOXL2) Prevents collagen crosslink STX-100 Monoclonal antibody against the integrin avb6 Prevent fibrogenesis Focus on Asthma guidelines update 7
8 Asthma Guidelines available National Asthma Education and Prevention Program (NAEPP) 7 Last updated 2007 Veteran s Administration/Department of Defense (VA/DoD) 8 Last updated 2009 Global Initiative for Asthma (GINA) 9 Last updated 2017 Not a guideline, but a practical approach Asthma Classification Based upon Guidelines 7-9 NAEPP & VA/DoD = Symptom-Based GINA = Control-Based Mild asthma: Well-controlled with PRN SABA or low dose ICS Moderate asthma: Well-controlled with low-dose ICS/LABA Severe asthma: Requires moderate or high dose ICS/LABA ± add-on or Remains uncontrolled despite this treatment Asthma - Focus in GINA Independent risk factors for exacerbations include: Ever intubated for asthma Uncontrolled asthma symptoms Having 1 exacerbation in last 12 months Low FEV 1 (measure at start of treatment, at 3-6M to assess personal best, and periodically) Incorrect inhaler technique and/or poor adherence Smoking Elevated FeNO (fractional exhaled nitric oxide) in adults with allergic asthma Obesity, pregnancy, blood eosinophilia 8
9 Asthma - Focus in GINA Focus on severe vs. uncontrolled Uncontrolled (more persistent symptoms/exacerbations, more easily controlled) Evaluate for Poor inhaler technique (require demonstration), Poor medication adherence (address cost, complexity, understanding) Co-morbidities Environmental factors Asthma control should be assessed at every interaction (even refills) Asthma - Focus in GINA Asthma-COPD Overlap Removed the word syndrome since not one disease Common, but not often seen in clinical trials Conflicting evidence makes treatment difficult Asthma never use LABA without ICS COPD start treatment with LABA and/or LAMA (without ICS) Repeat lung function test at least every 1-2 years Children with persistent asthma Reduced growth in lung function and may have accelerated decline as adults Asthma - Focus in GINA FeNO Not useful for diagnosis of asthma Elevated FeNO in allergic patient is risk factor for exacerbations Single measure of FeNo interpret with caution Not able to use to decide against inhaled steroids (not enough trial information) Other items reviewed Vitamin D no proof that improves asthma control Nasal steroids does help nasal symptoms, but does not help asthma control 9
10 Asthma - Focus in GINA Effect of steroids on growth of children Check height yearly (consider referral if growth delay) Poorly control asthma can affect growth In 1 st 1-2 years of inhaled steroids, growth velocity may be slowed Educate parents Possible effects on growth and importance of physical activity Impact on growth velocity is not cumulative or progressive Different in adult height may only be 0.7% Infant cough (chronic and no cold) associated with asthma No prevention strategy in utero found to prevent asthma Stepwise approach to control asthma symptoms and reduce risk Stepwise approach to control asthma symptoms and reduce risk 10
11 Stepwise approach to control asthma symptoms and reduce risk Stepwise approach to control asthma symptoms and reduce risk 11
12 Focus on COPD guidelines update COPD 2017 GOLD Guideline Changes 10 Definition of COPD COPD is a common, preventable and treatable disease that is characterized by persistent respiratory symptoms and airflow limitation that is due to airway and/or alveolar abnormalities usually caused by significant exposure to noxious particles or gases. Removed usually progressive and associated with an enhanced chronic inflammatory response in the airways and the lung COPD may be punctuated by acute worsening of respiratory symptoms, called exacerbations. Dyspnea, cough and/or sputum production are the most frequent symptoms; symptoms are commonly under-reported by patients. No longer use chronic bronchitis or emphysema COPD Guideline Changes Assessment Less emphasis on spirometry Severity based upon symptoms and not spirometry Symptoms and exacerbations correlate more with functional limitations and QOL 12
13 COPD Guideline Changes 10 Smoking Cessation Uses U.S. Preventive Services Task Force s guidelines for smoking cessation: Offer Nicotine replacement Cessation counseling Pharmacotherapy (varenicline, bupropion, or nortriptyline) Efficacy and safety of e-cigarettes is unclear COPD Guideline Changes 10 Oxygen - Not recommended for stable COPD patients without severe resting hypoxemia Did not improve QOL or outcomes Pharmacotherapy SABA/SAMA combination - stronger recommendation because superior to SABA or SAMA alone in improving symptoms and FEV 1 LABA/LAMA combination preferred over LABA/ICS Fewer exacerbations (vs. monotherapy or LABA/ICS) More improvement in FEV 1 (vs. monotherapy) ICS associated with pneumonia Elevated blood eosinophils LABA/ICS had more effect on decreasing exacerbations than LABA with high eosinophil counts Escalation and De-escalation plan COPD Guideline Changes 10 13
14 COPD Guideline Changes 10 COPD Guideline Changes 10 COPD Guideline Changes 10 Improved lung function, symptoms, and exacerbation 14
15 Keeping up with inhaled medications Inhaler Education Tips Only ½ to 1/3 of patients use inhalers correctly SABA separate puffs by 3 minutes Priming inhaler required for MDI (HFA or soft-mist) Initial use and if not used for specific number of days HFA closed-mouth technique recommended Dry Powder Breath out away from inhaler Require quick and deep inhalation Hold flat once activate the dose Handihaler and Neohaler must puncture capsule with piercing button Inhalers are supposed to be cleaned 15
16 Inhaler Education Tips Common Mistakes Not shaking inhalers 2 puffs at the same time (one breath) Poor technique (timing, inspiration, covering holes) Tilting a dry powder inhaler Not rinsing after steroid inhaler Not using scheduled doses when they should be scheduled Interventions known to improve adherence Shared decision making Comprehensive asthma education with home visits Inhaler reminders for missed doses Reviewing patient s refill records Information from GINA Choose Choose an appropriate device before prescribing. Consider medication options, arthritis, patient skills and cost. For ICS by pmdi, prescribe a spacer Avoid multiple different inhaler types if possible Check Check technique at every opportunity Can you show me how you use your inhaler at present? Identify errors with a device-specific checklist Correct Give a physical demonstration to show how to use the inhaler correctly Check again (up to 2-3 times) Re-check inhaler technique frequently, as errors often recur within 4-6 weeks Confirm Can you demonstrate correct technique for the inhalers you prescribe? Brief inhaler technique training improves asthma control Short-Acting Bronchodilators (SABA and SAMA) Drug Mechanism Dosing Frequency Delivery Type Wholesale Cost for 30-day supply Albuterol SABA (ProAir HFA, Proventil HFA, Ventolin HFA) 2 puffs QID and/or PRN MDI Neb Inhaler $50-60 Levalbuterol (Xopenex HFA) SABA 2 puffs QID and/or PRN MDI Neb Inhaler $70 Ipratropium (Atrovent HFA) SAMA 2 puffs QID and/or PRN Inhaler Neb Inhaler $285 16
17 Long-Acting Beta-Agonists (LABA) Drug Mechanism Dosing Frequency Delivery Type Wholesale Cost for 30-day supply Formoterol (Foradil Aerolizer) Indacaterol (Arcapta Neohaler) Olodaterol (Striverdi Respimat) Salmeterol (Serevent Diskus) LABA BID Inhaler $240 LABA Daily Neohaler DPI capsule $213 LABA Daily Respimat $155 LABA BID Diskus - DPI $322 Long-acting Muscarinic Antagonists (LAMA) Drug Mechanism Dosing Frequency Aclidinium (Tudorza Pressair) Glycopyrrolate (Seebri Neohaler) Tiotropium (Spiriva HandiHaler) (Spiriva Respimat) Umeclidinium (Incruse Ellipta) Delivery Type LAMA BID Pressair - DPI $242 LAMA BID Neohaler DPI capsule $297 LAMA Daily Inhaler Handihaler DPI capsule Respimat - Wholesale Cost for 30-day supply $315 LAMA Daily Ellipta - DPI $252 LAMA superior to LABA to prevent exacerbation of COPD (preferred if >2 exacerbations or hospital x 1 in last year) Beta-Agonist + Anticholinergic Drug Mechanism Dosing Delivery Type Frequency Albuterol/Ipratropium (Combivent Respimat) Formoterol/Glycopyrrolate (Bevespi Aerosphere) Indacaterol/Glycopyrrolate (Utibron Neohaler) Olodaterol/Tiotropium (Stiolto Respimat) Vilanterol/Umeclidinium (Anoro Ellipta) SABA + SAMA LABA + LAMA LABA + LAMA LABA + LAMA LABA + LAMA QID Respimat Neb BID MDI $334 BID Neohaler DPI capsule $297 Daily Respimat $315 Daily Ellipta - DPI $315 Wholesale Cost for 30-day supply Respimat $300 17
18 Inhaled Corticosteroids (ICS) Drug Mechanism Dosing Frequency Delivery Type Wholesale Cost for 30-day supply Beclomethasone (Qvar) Budesonide (Pulmicort Flexhaler Ciclesonide (Alvesco) Flunisolide (Aerospan) Fluticasone (Arnuity Ellipta) (Flovent HFA or Flovent Diskus) Mometasone (Asmanex Twisthaler) ICS BID MDI $150 ICS BID Flexhaler = DPI $170 ICS BID MDI $190 ICS BID MDI $250 ICS Daily or BID HFA - MDI $ Diskus/Elllipta DPI ICS BID Twisthaler - DPI $150 Beta-Agonists+Inhaled Corticosteroids (LABA/ICS) Drug Mechanism Dosing Frequency Formoterol/Budesonide (Symbicort) Salmeterol/Fluticasone (Advair Diskus, Advair HFA) (AirDuo Respiclick)-COPD only Formoterol/Mometasone (Dulera)-asthma only Vilanterol/Fluticasone (Breo Ellipta) Delivery Type LABA + ICS BID MDI $197 LABA + ICS BID Diskus-DPI HFA MDI AirDuo - Respiclick LABA + ICS BID MDI $240 LABA + ICS Daily Ellipta - DPI $297 Wholesale Cost for 30-day supply Advair $440 AirDuo $285 Generic $90 18
19 References 1. Godfrey AMK, Byrd RP, Ouellette DR, et al. Idiopathic pulmonary fibrosis. Accessed 17 August An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis: Executive Summary An Update of the 2011 Clinical Practice Guideline. Accessed 24 May Ofev [Prescribing Information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals; Esbriet [Prescribing Information]. South San Francisco, CA: Genentech; Santhosh L ATS guidelines on treatment of IPF released. Accessed 17 August Spagnolo P, Bonella F, Vasakova M, et al. Current and Future Therapies for Idiopathic Pulmonary Fibrosis Accessed 17 August National Asthma Education and Prevention Program's Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma-Full Report J Allergy Clin Immunol. 2007;120(5):S Management of Asthma Working Group: VA/DoD clinical practice guidelines for management of asthma in children and adults. Washington (DC): Department of Veterans Affairs, Department of Defense Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, Available from: Accessed 7 August Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017 at Accessed 17 Augusst FDA Approved Drugs for Pulmonary/Respiratory Diseases. Accessed 24 May PL Detail-Document, Inhalers for COPD. Pharmacist s Letter/Prescriber s Letter. January Clinical Resource, Correct Use of Inhalers. Pharmacist s Letter/Prescriber s Letter. January Pulmonary Medication Toolkit: Is yours up to date? Michelle Schymik, PharmD, BCPS Pharmacist for Deaconess Health System 19
Global Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline. MedStar Health
Global Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline MedStar Health These guidelines are provided to assist physicians and other clinicians in making decisions
More informationUp in FLAMES: Stable Chronic Obstructive Pulmonary Disease (COPD) Management. Colleen Sakon, PharmD BCPS September 27, 2018
Up in FLAMES: Stable Chronic Obstructive Pulmonary Disease (COPD) Management Colleen Sakon, PharmD BCPS September 27, 2018 Disclosures I have no actual or potential conflicts of interest 2 Objectives Summarize
More informationTRELEGY ELLIPTA (fluticasone-umeclidinium-vilanterol) aerosol powder
TRELEGY ELLIPTA (fluticasone-umeclidinium-vilanterol) aerosol powder Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific
More informationCOPD Update. Plus New and Improved Products for Inhaled Therapy. Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor
COPD Update Plus New and Improved Products for Inhaled Therapy Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor Disclosure The presenter has nothing to disclose concerning possible financial
More informationA Visual Approach to Simplifying Respiratory Drug Regimens
A Visual Approach to Simplifying Respiratory Drug Regimens Stephanie Cheng, PharmD, MPH, BCGP 3 Main Categories Inhaled Respiratory Drugs Binds to beta-2 receptors Relaxation of smooth muscles in the lung
More informationMDI Bonanza. Dwayne Griffin, DO
MDI Bonanza Dwayne Griffin, DO Bonanza 3. A MDI costing $200 - $500 per month SISYPHUS MDI Griffin Mountain Evolution of Deliver Systems for COPD in the US 2003 2009 2011 2013 2004 2012 2014 Prescribing
More informationA Visual Approach to Simplifying Respiratory Drug Regimens
Adverse Effects of Inhaled Medications A Visual Approach to Simplifying Respiratory Drug Regimens Stephanie Cheng, PharmD, MPH, BCGP June 28, 2017 Drug Category Beta 2 agonists antagonists Adverse Effects
More informationA Visual Approach to Simplifying Respiratory Drug Regimens
A Visual Approach to Simplifying Respiratory Drug Regimens Stephanie Cheng, PharmD, MPH, BCGP October 23, 2017 Learning Objectives Be able to list at least 3 major adverse effects of inhaled medications
More informationFerris State University College of Pharmacy MPA CE Symposium 2016 Paul Thill, PharmD, BCPS
Ferris State University College of Pharmacy MPA CE Symposium 2016 Paul Thill, PharmD, BCPS Objectives Categorize the new asthma and COPD inhalers in to existing or newly created categories Discuss the
More informationGlobal Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline. MedStar Health
Global Strategy f the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline MedStar Health These guidelines are provided to assist physicians and other clinicians in making decisions
More informationAsthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing
Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Diana M. Sobieraj, PharmD, BCPS Assistant Professor University of Connecticut School
More informationSelect Inhaled Respiratory Agents
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationThe Medical Letter. on Drugs and Therapeutics
The Medical Letter publications are protected by US and international copyright laws. Forwarding, copying or any other distribution of this material is strictly prohibited. For further information call:
More information12/18/2017. Disclosures. Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing
Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Diana M. Sobieraj, PharmD, BCPS Assistant Professor University of Connecticut School
More informationSTRIVERDI RESPIMAT (olodaterol hcl) aerosol
STRIVERDI RESPIMAT (olodaterol hcl) aerosol Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
More informationMEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 07/05/18 SECTION: DRUGS LAST REVIEW DATE: LAST CRITERIA REVISION DATE: ARCHIVE DATE:
CINQAIR (reslizumab) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs
More informationCOPD Medicine. No one ever showed me how to use this. Wendy Happel; RRT, COPD Educator Krystal Fedoris; RRT-NPS, BA, COPD Educator
Medicine. No one ever showed me how to use this. Wendy Happel; RRT, Educator Krystal Fedoris; RRT-NPS, BA, Educator 1 Taking prescriptions correctly Taking prescriptions can be a challenge Busy schedules
More informationThree s Company - The role of triple therapy in chronic obstructive pulmonary
Three s Company - The role of triple therapy in chronic obstructive pulmonary disease (COPD) October 26 th, 2018 Zahava Picado, PharmD PGY1 Pharmacy Resident Central Texas Veterans Healthcare System Zahava.Picado@va.gov
More informationNew and Novel Medications for Respiratory Care
New and Novel Medications for Respiratory Care JASON MOORE, PHARM.D. BCCCP CLINICAL STAFF PHARMACIST STORMONT-VAIL HEALTH Objectives Quick overview of the newest FDA-approved repiratory-related medications
More informationDrug Class Monograph
Drug Class Monograph Class: Inhaled Corticosteroids Drugs: Aerospan (flunisolide), Advair Diskus, Advair HFA (fluticasone/salmeterol), Alvesco (ciclesonide), Arnuity Ellipta (fluticasone furoate), Asmanex
More informationAIRDUO RESPICLICK (fluticasone-salmeterol) aerosol DULERA (mometasone furoate and formoterol fumarate dihydrate) aerosol
DULERA (mometasone furoate and formoterol fumarate dihydrate) aerosol Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific
More informationInhaled Corticosteroids Drug Class Prior Authorization Protocol
Inhaled Corticosteroids Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review
More informationInhaled Corticosteroids Drug Class Prior Authorization Protocol
Inhaled Corticosteroids Drug Class Prior Authorization Protocol Line of Business: Medi-Cal P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review
More informationAsthma/COPD Update with Inhaler Workshop
Asthma/COPD Update with Inhaler Workshop October 8, 2017 Nathan Samsa, DO, Pharm D, RPh, FACOI None Disclosures Agenda Asthma Updates COPD Updates Inhaler Workshop Medication Acronyms SABA: Short acting
More informationFASENRA (benralizumab)
FASENRA (benralizumab) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs
More informationCOPD Medications Coverage Summary Non-Insured Health Benefits Coverage SABA Bricanyl turbuhaler Yes Yes
COPD Medications Coverage Summary Drug Non-Insured Health Benefits Coverage SABA Bricanyl turbuhaler Yes Yes Ventolin MDI + generics Yes Yes Ventolin Diskus NO NO Yukon Pharmacare/Chronic Disease Program
More informationClinical Policy: Roflumilast (Daliresp) Reference Number: CP.PMN.46 Effective Date: Last Review Date: 08.18
Clinical Policy: (Daliresp) Reference Number: CP.PMN.46 Effective Date: 11.01.11 Last Review Date: 08.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationProvider Respiratory Inservice
Provider Respiratory Inservice 2 Welcome Opening Remarks We will cover: Definition of Asthma & COPD Evidence based guidelines for diagnosis, evaluation, and management of asthma Evidence based guidelines
More informationImpact of a Comprehensive COPD Therapeutic Interchange Program on 30-Day Readmission Rates in Hospitalized Patients
Impact of a Comprehensive COPD Therapeutic Interchange Program on 30-Day Readmission Rates in Hospitalized Patients Maren A. McGurran, PharmD, BCPS; Lisa M. Richter, PharmD, BCPS, BCCCP; Nathan D. Leedahl,
More informationAsthma COPD Update 2018
Asthma COPD Update 2018 Roger Hefflinger, Pharm.D. Clinical Associate Professor ISU COP Clinical Teaching Pharmacist Family Medicine Residency of Idaho In support of improving patient care, Idaho State
More informationCOPD: Treatment Update Property of Presenter. Not for Reproduction. Barry Make, MD Professor of Medicine National Jewish Health
COPD: Treatment Update Barry Make, MD Professor of Medicine National Jewish Health Disclosures Advisory board, consultant, multi-center trial, research funding, Data Safety Monitoring Board (DSMB), or
More informationIncorporating Newer Therapies and Strategies to Improve COPD Outcomes: A Practical Guide for Pharmacists. Learning Objectives.
Incorporating Newer Therapies and Strategies to Improve COPD Outcomes: A Practical Guide for Pharmacists Learning Objectives Identify the risk factors for COPD and the clinical features that differentiate
More informationKey features and changes to these four components of asthma care include:
Guidelines for the Diagnosis and Management of Asthma in Adults Clinical Practice Guideline MedStar Health These guidelines are provided to assist physicians and other clinicians in making decisions regarding
More informationDrug Effectiveness Review Project Summary Report
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationTest Your Inhaler Knowledge
A Breath of Fresh Air: Updates in COPD Management Jennifer Austin Szwak, PharmD, BCPS, DPLA University of Chicago Medicine The speaker has nothing to disclose Abbreviations COPD: Chronic obstructive pulmonary
More informationMichelle Zeidler, MD, MS
7/1/18 Chronic Obstructive Pulmonary Disease: Optimizing Outpatient Care & Reducing Exacerbations Michelle Zeidler, MD, MS Professor of Medicine, Pulmonary, Critical Care Medicine & Sleep Medicine, VA
More informationCOPD: Current Medical Therapy
COPD: Current Medical Therapy Angela Golden, DNP, FNP-C, FAANP Owner, NP from Home, LLC Outcomes As a result of this activity, learners will be able to: 1. List the appropriate classes of medications for
More informationCOPD: Preventable and Treatable. Lecture Outline. Diagnosis of COPD. COPD: Defining Terms
COPD: Preventable and Treatable Christopher H. Fanta, M.D. Partners Asthma Center Pulmonary and Critical Care Division Brigham and Women s Hospital Harvard Medical School Lecture Outline I. Diagnosis and
More informationImproving Outcomes in COPD
Neil MacIntyre MD Duke University Durham NC Current treatment guidelines f COPD focus Barriers to providing optimal treatment Diagnosis of COPD EXPOSURE TO RISK FACTORS AND/ OR SYMPTOMS sputum cough dyspnea
More informationreslizumab (Cinqair )
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationTake My Breath Away: COPD Update. Jason Henderson D.O. Warren Clinic Pulmonary & Critical Care
Take My Breath Away: Update Jason Henderson D.O. Warren Clinic Pulmonary & Critical Care Objectives 1. Recognize clinical signs and symptoms associated with chronic bronchitis and emphysema. 2. Describe
More informationMedications for Managing COPD in Hospice Patients. Jim Joyner, PharmD, CGP Director of Clinical Operations Outcome Resources
Medications for Managing COPD in Hospice Patients Jim Joyner, PharmD, CGP Director of Clinical Operations Outcome Resources Goal of medications in COPD Decrease symptoms and/or complications Reduce frequency
More informationCorrect Use of Inhaler Devices
PL Detail-Document #300206 This PL Detail-Document gives subscribers additional insight related to the Recommendations published in PHARMACIST S LETTER / PRESCRIBER S LETTER February 2014 Correct Use of
More informationQUANTITY LIMIT CRITERIA. BROVANA (arformoterol tartrate) SEREVENT DISKUS (salmeterol) STRIVERDI RESPIMAT (olodaterol)
Carelirst. +.V Family of health care plans DRUG CLASS COMBINATIONS QUANTITY LIMIT CRITERIA LONG ACTING BETA2-ADRENERGIC AGONIST, ORAL INHALATION BRAND NAME (generic) LONG-ACTING BETA2-ADRENERGIC AGONISTS:
More informationAsthma & COPD Medication Review. Hutchison Disclosures 2/16/2017. Objectives
Asthma & COPD Medication Review Anna Meador, PharmD, BCACP Assistant Professor/ Pharmacy Director McWhorter School of Pharmacy/ Christ Health Center Amber Hutchison, PharmD, BCPS Assistant Clinical Professor
More informationBalanced information for better care. Helping patients with COPD breathe easier
Balanced information for better care Helping patients with COPD breathe easier COPD is the third-leading cause of death in the U.S., following cancer and heart disease 1 FIGURE 1. Women now have a higher
More informationQuestion I was one of the first dry power devices available in the US Flovent, Serevent and Advair are all available in this device
What Device am I Class Side Effects History Potpourri Monitoring Tools 10 10 10 10 10 20 20 20 20 20 30 30 30 30 30 40 40 40 40 40 50 50 50 50 50 WHAT KIND OF DEVICE AM I? I was one of the first dry power
More informationIndividualizing and Optimizing Asthma Care. CFW 2018 Friday, April 13, 9:45 11:15 am Renaissance Austin Hotel in Austin, Texas
Individualizing and Optimizing Asthma Care CFW 2018 Friday, April 13, 9:45 11:15 am Renaissance Austin Hotel in Austin, Texas Speaker Disclosure Dr. Hawkins has disclosed that he has no actual or potential
More informationPresented by UIC College of Nursing
Presented by UIC College of Nursing Describe COPD. Identify red flags for a COPD exacerbation. Identify COPD triggers or risk factors. Differentiate between long-acting inhalers and emergency use inhalers.
More informationChronic Obstructive Pulmonary Disease 1/18/2018
Presented by UIC College of Nursing Describe COPD. Identify red flags for a COPD exacerbation. Identify COPD triggers or risk factors. Differentiate between long acting inhalers and emergency use inhalers.
More informationAsthma/COPD Update with Inhaler Workshop
Asthma/COPD Update with Inhaler Workshop October 8, 2017 Nathan Samsa, DO, Pharm D, RPh, FACOI None Disclosures Agenda Asthma Updates COPD Updates Inhaler Workshop Asthma Updates Asthma Updates SMART Trial
More informationDiagnosis and Management of Asthma
Supporting Evidence: Diagnosis and Management of Asthma The subdivision of this section is: Appendix B Tables Copyright 2016 by 1 Eleventh Edition/December 2016 Appendix B Asthma Summary Tables Class:
More informationChronic Obstructive Pulmonary Disease (COPD) KAREN ALLEN MD PULMONARY & CRITICAL CARE MEDICINE VA HOSPITAL OKC / OUHSC
Chronic Obstructive Pulmonary Disease (COPD) KAREN ALLEN MD PULMONARY & CRITICAL CARE MEDICINE VA HOSPITAL OKC / OUHSC I have no financial disclosures Definition COPD is a preventable and treatable disease
More informationPharmacist Objectives. Pulmonary Update. Outline. Technician Objectives. GOLD Guidelines. COPD Diagnosis 9/22/2017
Pharmacist Objectives Pulmonary Update Patty Marshik, PharmD Associate Professor University of New Mexico College of Pharmacy pmarshik@salud.unm.edu Discuss the new Global Initiative for Chronic Obstructive
More informationYour Inhaler Devices & You
1 Your Inhaler Devices & You COUNSEL ON THE APPROPRIATE USE OF A: METERED DOSE INHALER (MDI) DRY POWDER INHALER (DPI) DISCUSS THE APPROPRIATE USAGE OF A PEAK FLOW METER AND SPACER/HOLDING CHAMBER DEVICE
More informationMANAGING ASTHMA. Nancy Davis, RRT, AE-C
MANAGING ASTHMA Nancy Davis, RRT, AE-C What is asthma? Asthma is a chronic respiratory disease characterized by episodes or attacks of inflammation and narrowing of small airways in response to asthma
More informationCOPD Update: Focus on Intensifying LABA, LAMA and ICS Therapy
Update: Focus on Intensifying LABA, LAMA and ICS Therapy B.C. Provincial Academic Detailing Service February 2017 Background In Canada, approximately 20 inhaled medications are approved to treat Chronic
More informationREVISED RESPIRATORY MEDICATION USE QUESTIONNAIRE
REVISED RESPIRATORY MEDICATION USE QUESTIONNAIRE ID NUMBER: 0a) Date of Collection / / 0b) Staff Code Instructions: This form should be completed during the participant s clinic visit. 1) Are you regularly
More informationVA/DoD Clinical Practice Guideline Management of COPD Pocket Guide
VA/DoD Clinical Practice Guideline Management of COPD Pocket Guide MODULE A: MAAGEMET OF COPD 1 2 Patient with suspected or confirmed COPD presents to primary care [ A ] See sidebar A Perform brief clinical
More informationCOPD: GOLD guidelines Ijlal Babar, MD Medical Director Pulmonary CCM, Pulmonary Hypertension Center SRHS
COPD: GOLD guidelines 2017 Ijlal Babar, MD Medical Director Pulmonary CCM, Pulmonary Hypertension Center SRHS Introduction The Global Initiative for Chronic Obstructive Lung Disease (GOLD) program was
More informationImproving Outcomes in COPD. Improving Outcomes in COPD 4/4/2018
Updates 2018 Neil MacIntyre MD Duke University Durham NC. Barnes PJ. N Engl J Med. 2000;343:269-80. 1 COPD spectrum Proximal predominant (large airways) mucus gland hypertrophy (cough/sputum) reduced respiraty
More informationUsing Inhaled Corticosteroids as Needed for Asthma: giving patients relief or leaving them breathless?
Using Inhaled Corticosteroids as Needed for Asthma: giving patients relief or leaving them breathless? Lindsay Thomas, Pharm.D. PGY2 Ambulatory Care Resident Department of Pharmacotherapy and Pharmacy
More informationChronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease CareOregon Pharmacy Abridged sample of presentation content Home Equipment Pathophysiology Exacerbations Guidelines Lifestyle Modification Medication Management Sample
More informationWomen Beware-The Threat of COPD
Page 1 Speaker: Catherine Cooke attained her Bachelor in Pharmacy from the University of Iowa and then went on to receive her Pharm.D. from the Medical University of South Carolina. Subsequently, she completed
More informationIf you require this document in another format such as Braille, large print, audio or another language please contact the Trusts Communications Team
MANAGEMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN ADULTS Summary statement: How does the document support patient care? Staff/stakeholders involved in development: Job titles only Division:
More informationPFT s / 2017 Pulmonary Update. Eric S. Papierniak, DO University of Florida NF/SG VHA
PFT s / 2017 Pulmonary Update Eric S. Papierniak, DO University of Florida NF/SG VHA Outline Overview of pulmonary function testing Uses/indications/limitations Technical aspects Basics of interpretation
More informationCOPD. Understanding. An educational health series from National Jewish Health IN THIS ISSUE. What is COPD? 2. How is COPD Managed?
Understanding COPD The Mount Sinai National Jewish Health Respiratory Institute was formed by the nation s leading respiratory hospital National Jewish Health, based in Denver, and top ranked academic
More informationUpdate on Pulmonary Diseases. Jeffrey Lessar, MD
Update on Pulmonary Diseases Jeffrey Lessar, MD 1 No disclosures to make No conflicts 2 Goals Update on key changes in Pulmonary Therapy 3 Spirometry Spirometry FEV1- forced expiratory Volume in 1 Sec
More informationNancy Davis, RRT, AE-C
Nancy Davis, RRT, AE-C Asthma Statistics 25.6 million Americans diagnosed with asthma 6.8 million are children 10.5 million missed school days per year 14.2 lost work days for adults Approximately 10%
More informationTHE COPD PRESCRIBING TOOL
THE COPD PRESCRIBING TOOL Revised edition, 2017 www.bpac.org.nz/copd CLASSIFICATION The COPD prescribing tool This tool provides pharmacological treatment options for patients with COPD based on their
More informationCOPD Robert Schilz DO, PhD Pulmonary, Critical Care and Sleep Medicine University Hospitals Case Medical Center
COPD 2018 GOLD 2017 Report Global Initiative for Chronic Obstructive Lung D isease COPYRIGHTED MATERIAL- DO NOT COPY OR DISTRIBUTE GLOBAL STRATEGY FOR THE DIAGNOSIS, MANAGEMENT, AND PREVENTION OF CHRONIC
More informationRespiratory Health. Asthma and COPD
Respiratory Health Asthma and COPD Definition of asthma Working definition by AAH 2014: Chronic lung disease Can be controlled not cured Large variation in lung function Large variation in respiratory
More informationWomen Beware The Threat of COPD
Page 1 Women Beware The Threat of COPD Catherine E. Cooke, PharmD, BCPS, PAHM President, PosiHealth, Inc. & Clinical Associate Professor, University of Maryland School of Pharmacy Supported by an education
More informationA Breath of Fresh Air? An update of novel inhalers used for the treatment of asthma and COPD
A Breath of Fresh Air? An update of novel inhalers used for the treatment of asthma and COPD Chris Federico PharmD, BCACP RIPF Kimberly McDonough Spring Seminar May 4, 2016 Disclosure I have no actual
More informationEnd Stage COPD Guidance Document
End Stage COPD Guidance Document Suggested Guidelines for the Determination of Hospice Eligibility A patient with severe chronic pulmonary disease that meets the following criteria may be eligible for
More informationPrescribing guidelines: Management of COPD in Primary Care
Prescribing guidelines: Management of COPD in Primary Care Establish diagnosis of COPD in patients 35 years with appropriate symptoms with history, examination and spirometry (FEV1/FVC ratio < 70%) Establish
More informationTHE CHALLENGES OF COPD MANAGEMENT IN PRIMARY CARE An Expert Roundtable
THE CHALLENGES OF COPD MANAGEMENT IN PRIMARY CARE An Expert Roundtable This activity is supported by an educational grant from Sunovion Pharmaceuticals Inc. COPD in the United States Third leading cause
More informationNintedanib and Pirfenidone: New Medications in the Management of Idiopathic Pulmonary Fibrosis
Nintedanib and Pirfenidone: New Medications in the Management of Idiopathic Pulmonary Fibrosis Brad Zimmermann, PharmD, MBA Pharmacy Grand Rounds May 02, 2017 Rochester, Minnesota 2017 MFMER slide-1 Objectives
More informationChronic Obstructive Pulmonary Disease
Quality Department Guidelines for Clinical Care Ambulatory COPD Guideline Team Team Leader Davoren A Chick, MD General Medicine Team Members Paul J Grant, MD General Medicine R Van Harrison, PhD Learning
More informationAsthma medications: Know your options - MayoClinic.com. Asthma medications: Know your options
MayoClinic.com reprints This single copy is for your personal, noncommercial use only. For permission to reprint multiple copies or to order presentation-ready copies for distribution, use the reprints
More informationReference Guide for Caring for Pediatric Patients with Asthma
Reference Guide for Caring for Pediatric Patients with Asthma Co-Chair: Nancy Cantey Banasiak, DNP, PPCNP-BC, APRN Co-Chair: Deborah Hickman, DNP, APRN-CNP, CPNP-PC, NNP-BC Asthma and Allergy SIG Members
More informationAsthma. Definition. Symptoms
Asthma Definition Asthma is a condition in which your airways narrow and swell and produce extra mucus. This can make breathing difficult and trigger coughing, wheezing and shortness of breath. For some
More informationcontinuing education for pharmacists
continuing education for pharmacists Volume XXXIV, No. 12 Asthma: Approaches to Treatment and New Therapies Cortney M. Mospan, PharmD, BCACP, CGP, Assistant Professor of Pharmacy, Wingate University School
More informationSABA: VENTOLIN EVOHALER (SALBUTAMOL) SAMA: ATROVENT IPRATROPIUM. Offer LAMA (discontinue SAMA) OR LABA
COPD GUIDELINES DIAGNOSIS >35 years of age Symptoms of cough, breathlessness, sputum, wheeze, Risk factor (SMOKING) Spirometry (post bronchodilator) FEV1/FVC = 0.7 ENCOURAGE PATIENTS TO BRING INHALERS
More information10/18/2012. Penn State University Children s Hospital JODIE STABINSKI CRNP MSN AE-C
Penn State University Children s Hospital JODIE STABINSKI CRNP MSN AE-C Daily: Long-Term Control Corticosteroids (inhaled and systemic) Long-acting beta 2 -agonists (Serevent, Foradil) Methylxanthines
More informationGINA. At-A-Glance Asthma Management Reference. for adults, adolescents and children 6 11 years. Updated 2017
GINA At-A-Glance Asthma Management Reference for adults, adolescents and children 6 11 years Updated 2017 This resource should be used in conjunction with the Global Strategy for Asthma Management and
More informationMEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Asthma/COPD P&T DATE 12/14/2017 CLASS:
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Asthma/COPD P&T DATE 12/14/2017 CLASS: LOB: Respiratory Disorders Medi-Cal REVIEW HISTORY (MONTH/YEAR) 12/17,12/16, 5/15,
More informationRespiratory Medications and Devices Update 2/15
Respiratory Medications and Devices Update 2/15 Dewey Hahlbohm, PA-C, AE-C Wendy Brown, Pharm.D., MPAS, PA-C, AE-C Objectives! Review mechanism of action for asthma pharmacologic agents! Describe key patient
More informationII: Moderate Worsening airflow limitations Dyspnea on exertion, cough, and sputum production; patient usually seeks medical
Table 3.1. Classification of COPD Severity Stage Pulmonary Function Test Findings Symptoms I: Mild Mild airflow limitations +/ Chronic cough and sputum production; patient unaware of abnormal FEV 1 80%
More information2017 GOLD Report. Is it worth its weight in GOLD??? CSHP-NB Fall Education Day September 30, 2017
2017 GOLD Report Is it worth its weight in GOLD??? CSHP-NB Fall Education Day September 30, 2017 Lauren Munro; BSc(Pharm) Amanda Burns; BSc(Pharm) Pharmacy Residents The Moncton Hospital Objectives Explain
More informationGlobal Initiative for Asthma (GINA) What s new in GINA 2017?
Global Initiative for Asthma (GINA) GINA Global Strategy for Asthma Management and Prevention Asthma-COPD overlap The word syndrome has been removed from the previous term asthma-copd overlap syndrome
More informationINHALERS for COPD INTRODUCTION. Types of inhalers. Inhaler technique. MDIs for COPD WET AEROSOLS. Dr Christopher Worsnop
INHALERS for COPD Dr Christopher Worsnop Department of Respiratory Medicine Austin Hospital INTRODUCTION Most drugs for COPD are given via inhalers. This reduces the dose that needs to be given and delivers
More informationCHRONIC OBSTRUCTIVE PULMONARY DISEASE
CHRONIC OBSTRUCTIVE PULMONARY DISEASE INCIDENCE UP TO 380,000 PEOPLE IN IRELAND HSE FIGURES 110,000 DIAGNOSED AND 200,000 UNDIAGNOSED. AFFECTS MORE MEN THAN WOMEN BUT RATES ARE RISING 1500 DEATHS PER YEAR
More informationClass Update: Asthma / COPD Medications
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationCOPD: A Renewed Focus. Disclosures
COPD: A Renewed Focus Heath Latham, MD Assistant Professor Division of Pulmonary and Critical Care Medicine Disclosures No Business Interests No Consulting No Speakers Bureau No Off Label Use to Discuss
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Seebri Neohaler) Reference Number: CP.CPA.150 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy
More informationAddress Comorbidities
Greater Manchester COPD Management Plan Non-pharmacological management for ALL patients Smoking Cessation Annual Flu Vaccination Pulmonary Rehabilitation Increase daily activity Inhaler Technique Measure
More informationMedicines Management of Chronic Obstructive Pulmonary Disease (COPD)
Medicines Management of Chronic Obstructive Pulmonary Disease (COPD) (Chronic & Acute) Guidelines for Primary Care Guideline Authors: Shaneez Dhanji (Wandsworth CCG) Samantha Prigmore (St George s Hospital)
More informationInhaled Corticosteroid Dose Comparison in Asthma
This Clinical Resource gives subscribers additional insight related to the Recommendations published in April 2017 ~ Resource #330402 Inhaled Corticosteroid Dose Comparison in Asthma The chart below provides
More informationCOPD The New Epidemic. Peter Lin MD CCFP Director Primary Care Initiatives Canadian Heart Research Centre
COPD The New Epidemic Peter Lin MD CCFP Director Primary Care Initiatives Canadian Heart Research Centre Conflict Disclosure Information Speaker: Dr. Peter Lin Title of Talk: COPD The New Epidemic Financial
More information